N-[2-[Bis(1-Methylethyl)Amino]Ethyl]-2-Oxo-1-Pyrrolidineacetamide Sulfate

Dry blending of pramiracetam sulfate with direct-compression excipients proceeds in a tumble blender operating at 25 rpm for 15 minutes following geometric dilution of the active. A representative batch formula consists of 300 mg pramiracetam sulfate (equivalent to 250 mg pramiracetam free base), microcrystalline cellulose PH-102 (120 mg), pregelatinized maize starch (50 mg), crosscarmellose sodium (15 mg), colloidal silicon dioxide (3 mg), and magnesium stearate (3 mg)—targeting a 491 mg total core weight for a 0.750″ round, flat-faced beveled-edge tablet. Prior to weighing, the API must undergo vacuum drying at 40 °C for 4 hours to a loss-on-drying value below 0.5% w/w; the sulfate counterion confers hygroscopicity that elevates moisture content above 1.2% within 30 minutes of exposure to 55% RH, requiring a processing suite held at 35–40% RH maximum. Compression is performed on a 12-station rotary tablet press (tooling type B) fitted with force feeders, at target compression forces of 8–12 kN. Hardness measured across 20 tablets per sampling interval must fall within 80–120 N, with a friability not exceeding 0.8% after 100 drum revolutions per USP <1216>. In vitro dissolution employs USP Apparatus 2 (paddles) at 50 rpm in 900 mL of 0.1 N HCl at 37 ± 0.5 °C; acceptance criterion Q is set at 75% released within 45 minutes, with a relative standard deviation ≤ 6.0% for 12 individual units. Content uniformity is assessed in accordance with USP <905>; the acceptance value (AV) must be ≤ 15.0 for the first 10 dosage units and remain ≤ 15.0 when expanded to 30 units. Packaging in cold-form aluminium/aluminium blister cavities with integrated desiccant sachets sustains a 36-month shelf life at 25 °C/60% RH long-term stability ICH storage. A known processing incompatibility exists with primary and secondary amine-bearing colorants (e.g., certain FD&C lakes), where Schiff base adducts accumulate at the tablet surface, detectable by HPLC as late-eluting peaks at relative retention times 2.3–2.8.

How Does the Sulfate Salt Enable Room-Temperature Isotonic Parenteral Formulations?

The aqueous solubility of pramiracetam sulfate at 25 °C exceeds 200 mg/mL, eliminating the requirement for co-solvents or cyclodextrin complexation in formulations intended for intravenous or deep intramuscular administration. A typical small-volume parenteral is prepared at a concentration of 20 mg/mL pramiracetam base equivalent in Water for Injection, adjusted to an osmolality of 280–320 mOsm/kg with sodium chloride and buffered to pH 5.8–6.2 using 10 mM disodium hydrogen phosphate/citric acid buffer. The solution is filled into 5 mL Type I borosilicate glass ampoules under nitrogen overlay and sterilized by autoclaving at 121 °C for 15 minutes; however, a 0.5–1.2% increase in total related substances has been documented post-termination, making aseptic filtration through 0.22 µm PVDF membranes the preferred terminal sterilization method where facility capabilities permit. Terminal moist-heat sterilization is acceptable only when a validated formulation-specific overkill design demonstrates a post-sterilization mean degradation product level ≤ 1.5%. Photostability data per ICH Q1B Option 1 mandate secondary packaging that blocks UV radiation below 380 nm; solutions stored in amber ampoules or overwrapped with black low-density polyethylene shrink film meet a photostability endpoint of total impurities ≤ 0.8% after 1.2 million lux·h visible and 200 W·h/m² UVA exposure. Bacterial endotoxins are controlled to < 0.50 EU/mg of active using the gel-clot or kinetic chromogenic method of USP <85>. At concentrations above 50 mg/mL the dynamic viscosity rises to 12–15 mPa·s, which complicates syringeability through 21-gauge needles; dilution or warming to 30 °C may be required during administration in preclinical large-animal catheterized models. Sealed ampoules are subjected to 100% visual inspection with light intensity ≥ 2,000 lux against black and white backgrounds, rejecting units with visible particulates ≥ 50 µm.

A reference standard qualification program for pramiracetam sulfate is established with a purity assignment by mass balance combining HPLC area percent, Karl Fischer water content, residual solvents by headspace GC, and sulfated ash per general chapter USP <281>. The liquid chromatographic method employs an end-capped octadecylsilane column (150 mm × 4.6 mm, 5 µm particles), thermostatted at 30 °C, with a mobile phase consisting of phosphate buffer (pH 3.0) and acetonitrile (75:25 v/v) delivered isocratically at 1.0 mL/min. Detection is by UV absorbance at 205 nm, where the amide chromophore gives a specific extinction coefficient suitable for quantitation down to the 0.05% reporting threshold. Under these conditions, pramiracetam elutes at approximately 8.2 minutes, while the primary hydrolysis product, piracetam, appears at a relative retention time of 0.45. System suitability requires resolution between the main peak and the nearest impurity compound to be not less than 2.0, a tailing factor not more than 1.5 calculated at 5% peak height, and relative standard deviation of peak area from six replicate injections ≤ 1.0%. For impurity profiling, the test solution is prepared at 1.0 mg/mL and spiked with a 0.1% level of known process impurities—including the N-desalkyl intermediate and the open-ring acid hydrolysis product—to verify resolution before each analytical sequence. Quantitation of genotoxic potential requires an LC-MS/MS method with electrospray ionization in positive ion mode targeting the diisopropylethylenediamine fragment at m/z 131.2→58.1, with a limit of quantitation validated at 0.1 ppm relative to the API. These analytical reference standards are stored in sealed amber glass vials at –20 °C, equilibrated to ambient temperature before opening to prevent moisture condensation, and requalified every 12 months against a freshly prepared master standard.

If the Morris Water Maze Protocol Requires Chronic Oral Dosing in Rodent Models of Cholinergic Deficit

Preclinical behavioral studies utilizing pramiracetam sulfate routinely prepare daily suspensions at 30–50 mg/mL in 0.5% w/v methylcellulose (400 cP viscosity grade) in purified water, which is then administered by oral gavage at a volume of 10 mL/kg body weight to yield doses of 100–300 mg/kg pramiracetam free base. The suspension must be continuously stirred with a magnetic bar or overhead paddle during the entire dosing session to prevent sedimentation; homogeneity is verified by sampling three aliquots from the top, middle, and bottom of the vessel at the beginning, midpoint, and end of a dosing window and assaying against the theoretical concentration, with acceptance criteria of 90.0–110.0% for each aliquot. Laboratory chow is withdrawn 12 hours prior to the probe trial to standardize metabolic state across treatment groups. For intraperitoneal injection studies, the sulfate salt is reconstituted in sterile isotonic saline at 50 mg/mL and passed through a 0.45 µm polyethersulfone syringe filter for immediate use, as the solution exhibits a discernible pH drift toward alkalinity (ΔpH +0.4 to +0.7 units) when stored beyond 8 hours at room temperature, attributable to slow carbonate absorption. Dose volumes are calibrated according to each animal’s daily body weight to maintain the target mg/kg dose; weekly body weight gain is monitored and must remain within ±15% of the vehicle control group mean to satisfy general health criteria. The behavioral endpoint typically measured is escape latency in seconds, with statistical significance assessed by two-way repeated-measures ANOVA followed by post-hoc Dunnett’s test at p < 0.05. Published data for the specific combination of pramiracetam sulfate with the muscarinic antagonist scopolamine hydrobromide (1 mg/kg i.p.) reveals a partial reversal of acquisition deficits when the drug is administered 60 minutes pre-training, although quantitative dose-response curves for this salt form remain limited to a small number of independent replication studies.

Co-Micronized Binary Blends with Citicoline for Enhanced Frontal Cortex Bioavailability

Compounding pramiracetam sulfate with citicoline monosodium aims to potentiate phospholipid metabolism and cholinergic tone via complementary biochemical mechanisms. A 1:2 weight ratio of pramiracetam sulfate to citicoline is pre-blended in a V-shell blender for 10 minutes and passed through a spiral jet mill with a classifier speed of 17,000 rpm and nitrogen pressure of 8.5 bar, reducing the median particle size d₅₀ of both components to below 12 µm. Differential scanning calorimetry scans at 10 °C/min over 30–300 °C must show no new endothermic events and no shift in the melting onset temperatures exceeding ±2 °C relative to the pure components to confirm the absence of eutectic formation or solid-state interactions. The cohesive micronized powder is filled into size 0 hard gelatin capsules with 2% w/w magnesium stearate added post-micronization as an extragranular lubricant; dissolution testing in 900 mL of 0.1 N HCl using USP Apparatus 1 (baskets) at 100 rpm demonstrates >85% release of both actives within 30 minutes. A validated HPLC method with dual-wavelength detection at 205 nm (pramiracetam) and 272 nm (citicoline) resolves the two APIs and their primary degradants on a single chromatographic run, enabling simultaneous dissolution profiling in a composite medium without interference. Because citicoline is hygroscopic and pramiracetam sulfate absorbs significant surface moisture below 40% RH, capsule filling operations are protected by a dry-air envelop with a dew point of –40 °C or lower; filled capsules are packaged immediately in high-density polyethylene bottles containing 2-gram molecular sieve desiccant canisters and induction-sealed under a nitrogen headspace. The compatibility data below was generated from 4-week stress storage at 50 °C/75% RH with binary mixtures at practical excipient-to-drug ratios.

Jet-milling of pramiracetam sulfate is conducted with a 4-inch pancake mill (fluid energy-type) using nitrogen as the grinding gas at a venturi pressure of 8 bar and a grinding pressure of 7 bar, with a metered feed rate of 25 g/min. The un-milled API, which typically exhibits a d₅₀ of 45–65 µm from the final re-crystallization and tray-drying step, is reduced to a target d₅₀ of 5–8 µm and a d₉₀ not exceeding 18 µm as measured by laser diffraction (Malvern Mastersizer 3000, wet dispersion in 0.1% w/v sorbitan monooleate in cyclohexane, refractive index model for organic crystalline materials). Atmospheric humidity in the milling suite is held below 30% RH, because the milled product gains moisture rapidly during discharge from the cyclone collector—agglomeration and a 15–20% loss in tablet compactibility are observed when the powder bed equilibrates above 55% RH. The specific surface area, determined by krypton adsorption BET method, increases from roughly 0.5 m²/g to 3.2 m²/g, and the Carr index (compressibility) transitions from 15 (good flow) to 38 (very cohesive), necessitating the use of a vibratory feeder rather than a gravity-fed system during subsequent capsule filling or tableting. To mitigate amorphous content generated by high-energy particle collisions—detected as a broad halo in the X-ray powder diffraction pattern between 10° and 25° 2θ superimposed on the crystalline reflections—the micronized powder is annealed in a vacuum oven at 50 °C and –0.9 bar gauge for 4 hours, reducing the amorphous fraction to below the 2% detection limit of the XRPD method. Following annealing, the lot is re-sieved through a 150 µm mesh to break up soft agglomerates and stored in double polyethylene bags inside a sealed aluminium canister with silica gel until use. The amorphization-annealing cycle is controlled stringently because residual amorphous content above 3% has been correlated with delayed dissolution— Q45 min values dropping from 95% to as low as 58%—when the product is subsequently formulated into immediate-release tablets with insoluble diluents.

Forced Degradation Studies Reveal a pH-Dependent Amide Hydrolysis Pathway Unique to the Protonated State

When pramiracetam sulfate is subjected to 0.1 N HCl at 80 °C for 48 hours, the principal degradant identified by liquid chromatography coupled with high-resolution mass spectrometry is piracetam (2-oxo-1-pyrrolidineacetamide), arising from cleavage of the exocyclic amide linkage; the pseudo-first-order rate constant k has been determined to be approximately 1.2 × 10⁻² h⁻¹ under these conditions. Under alkaline stress (0.05 N NaOH, 40 °C, 24 hours), hydrolytic degradation accelerates dramatically (k ≈ 0.45 h⁻¹), producing piracetam and N,N-diisopropylethylenediamine in an equimolar stoichiometry confirmed by charged aerosol detection. Oxidative treatment with 3% H₂O₂ at 25 °C for 6 hours yields a profile of N-oxide species eluting at relative retention times of 1.37–1.62 with respect to the main peak; these photo-oxidation products themselves degrade further when exposed to ICH Q1B Option 1 light conditions, generating secondary low-molecular-weight fragments detectable by UV absorbance extending to 260 nm. The pH-stability profile reveals a maximum solution stability plateau between pH 4.5 and 6.0, where the protonated diisopropylaminoethyl side chain electrostatically shields the adjacent amide from nucleophilic attack. Thermal degradation in the solid state above 90 °C under dry nitrogen is minimal, with only 0.15% total impurity increase after 14 days, confirming that the pathway is primarily hydrolytic rather than pyrolytic. For solid dosage forms, the following degradation rate data have been compiled under accelerated and long-term conditions, informing packaging and formulation decisions.

These degradation pathways dictate a formulation pH control no higher than 6.5 for liquid preparations and the absolute exclusion of alkalizing buffer systems. Solid oral dosage forms packaged in amber high-density polyethylene bottles induction-sealed under nitrogen show total impurities held to ≤0.5% through 36 months at 25 °C/60% RH, while blister packaging using PVC/PCTFE film provides equivalent protection only when the formed cavities are back-flushed with dry nitrogen immediately prior to lidding. Any routine storage protocol that departs from these moisture-barrier and light-shielding measures results in a measurable upward trend of the piracetam peak at the 18-month pull point, which is the critical quality attribute monitored during ongoing stability studies per ICH Q1A(R2).